Key result
Myocardial 123I-MIBG scintigraphy enters pilot testing to assess utility in dementia with Lewy bodies trials.
Why the study?
The study was conducted to establish the basis for a myocardial 123I-MIBG scintigraphy study in the US and assess its potential utility in prodromal DLB clinical trials.
Does myocardial MIBG-scintigraphy have potential utility in prodromal dementia with Lewy bodies clinical trials?
Does myocardial MIBG-scintigraphy have potential utility in prodromal dementia with Lewy bodies clinical trials?
This pilot study aims to establish the basis for using myocardial MIBG scintigraphy in prodromal dementia with Lewy bodies clinical trials in the US.
Supports MIBG-scintigraphy feasibility in US prodromal DLB trials; leaves open its diagnostic role pending validation.
To establish the basis for a myocardial 123I-metaiodobenzylguanidine scintigraphy (MIBG-scintigraphy) study in the US and to assess its potential utility in prodromal dementia with Lewy bodies (DLB) clinical trials.
No takes yet. Share an insight, caveat, or question.
Miyagawa et al. (2026) studied this question. Myocardial 123I-MIBG scintigraphy is being investigated in a pilot study to assess its potential utility for clinical trials in prodromal and overt dementia with Lewy bodies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: